OS Therapies

Directions Website Contact the business

OS Therapies OS Therapies (OSTX) is the leading Osteosarcoma biotechnology company.

OS Therapies’ work in comparative oncology is rooted in the development history of OST-HER2.Canine osteosarcoma research...
10/12/2026

OS Therapies’ work in comparative oncology is rooted in the development history of OST-HER2.

Canine osteosarcoma research helped catalyze the human clinical development of the Listeria-based immunotherapy platform. That early connection continues today through two separate programs focused on naturally occurring osteosarcoma.

OS Therapies is advancing OST-HER2 in human osteosarcoma, while its subsidiary, OS Animal Health, is focused on advancing the therapy for canine osteosarcoma.

Learn more about the company's work: https://ostherapies.com/

OS Therapies’ latest three-year overall survival data for OST-HER2 (Herlystic™) is an important milestone for the compan...
10/08/2026

OS Therapies’ latest three-year overall survival data for OST-HER2 (Herlystic™) is an important milestone for the company’s investigational immunotherapy for osteosarcoma.

In a new interview with Next Big Story, CEO Paul Romness discusses the statistically significant survival benefit observed in the Phase 2b trial compared with the combined historical control, along with the significance of overall survival data as OS Therapies engages with regulators in the U.S., U.K., EU and Australia.

The discussion provides additional context on the clinical trial and the latest data supporting the continued regulatory development of OST-HER2.

Watch the interview: https://www.youtube.com/watch?v=qMF2zvMdYdI

OS Therapies (OST) is a clinical-stage cancer immunotherapy company...

OST-HER2 is being advanced through separate human and canine osteosarcoma programs.The connection between those programs...
10/08/2026

OST-HER2 is being advanced through separate human and canine osteosarcoma programs.

The connection between those programs began with canine osteosarcoma research that helped catalyze development of the OST-HER2 platform for human use. Through comparative oncology, OS Therapies has incorporated insights from naturally occurring osteosarcoma in both species into the development history of the therapy.

Learn more: https://ostherapies.com/

OS Animal Health, a subsidiary of OS Therapies (NYSE: OSTX), has received feedback from the USDA on its commercial devel...
10/07/2026

OS Animal Health, a subsidiary of OS Therapies (NYSE: OSTX), has received feedback from the USDA on its commercial development pathway for OST-HER2 in canine osteosarcoma.

The USDA provided guidance on clinical efficacy, clinical safety, non-clinical and manufacturing (CMC) ahead of OS Animal Health's upcoming conditional licensure request. OS Animal Health intends to seek conditional licensure based on efficacy data it has already generated, including prevention of metastasis, metastatic disease control and prevention of amputation in frontline osteosarcoma.

OS Animal Health hopes to launch OST-HER2 commercially for dogs in the United States in 2027.

Read the press release: https://bit.ly/4yDoFyB

OS Therapies has announced statistically significant final three-year overall survival results from the Phase 2b trial o...
10/06/2026

OS Therapies has announced statistically significant final three-year overall survival results from the Phase 2b trial of Herlystic (OST-HER2) in fully resected pulmonary metastatic osteosarcoma.

Patients treated with Herlystic achieved a 72.7% three-year overall survival rate compared to 45.8% in comparable combined historical controls, with a statistically significant p-value of 0.0006. This marks continued progress as we prepare to complete submissions for early market access across the U.S., U.K., Europe, and Australia.

We are deeply grateful to the clinical investigators, patients, and families who made this milestone possible as we advance our mission to bring a much-needed treatment option to patients fighting osteosarcoma.

Read the announcement: https://bit.ly/4i4dmtb

The name OST-HER2 reflects the scientific foundation of OS Therapies' lead program.The "HER2" refers to the tumor-associ...
10/05/2026

The name OST-HER2 reflects the scientific foundation of OS Therapies' lead program.

The "HER2" refers to the tumor-associated antigen targeted by the investigational therapy. OST-HER2 uses a Listeria-based platform designed to deliver HER2-targeted antigens and stimulate an immune response against HER2-expressing tumor cells.

OS Therapies is studying this approach in osteosarcoma through its OST-HER2 clinical program.

Learn more: https://bit.ly/3QX7irr

What is OST-HER2?OS Therapies' lead investigational therapy is built around a live-attenuated Listeria monocytogenes pla...
10/02/2026

What is OST-HER2?

OS Therapies' lead investigational therapy is built around a live-attenuated Listeria monocytogenes platform designed to deliver HER2-targeted antigens directly into the immune system.

The program brings together the company's Listeria-based platform, HER2 targeting and a clinical development strategy focused on osteosarcoma.

Learn more about OST-HER2: https://bit.ly/3QX7irr

Please welcome Kerry Clem, our new Chief Commercial Officer, and Frank Knuettel II, our new Chief Financial Officer.Kerr...
10/01/2026

Please welcome Kerry Clem, our new Chief Commercial Officer, and Frank Knuettel II, our new Chief Financial Officer.

Kerry leads commercialization strategy and launch planning for Herlystic™ (OST-HER2), our investigational immunotherapy in osteosarcoma.

Frank brings expertise in finance and accounting operations and corporate governance as OS Therapies moves toward commercialization.

https://bit.ly/47toTMF

OST-HER2 now has both its WHO-approved proprietary name, Herlystic™, and nonproprietary name, daznelimgene lisbac, follo...
10/01/2026

OST-HER2 now has both its WHO-approved proprietary name, Herlystic™, and nonproprietary name, daznelimgene lisbac, following approval of the brand name by the World Health Organization.

With both names approved, OS Therapies says it is moving ahead with planned early market access regulatory filings. The company expects to submit to the U.K.’s MHRA in the coming weeks, based on the 2.5-year and interim 3-year overall survival data reviewed in its recent Scientific Advice Meeting, followed by planned submissions to the FDA, EMA and TGA once final 3-year overall survival data is available.

ICYMI, read the announcement: https://bit.ly/4rrArJo

The latest Herlystic data and regulatory discussions are setting the stage for the next phase of the program. In a new i...
09/30/2026

The latest Herlystic data and regulatory discussions are setting the stage for the next phase of the program. In a new interview with The Big Biz Show, OS Therapies CEO Paul Romness discussed the reported overall survival data, the planned confirmatory study and the need for additional treatment options for patients with pulmonary metastatic osteosarcoma.

Recent developments around Project Orbis and the WHO approval of Herlystic as the brand name for OST-HER2 are part of the broader discussion.

Watch the interview: https://bit.ly/4e47zBx

Paul Romness, Chair, CEO and President of OS Therapies, discusses t...

Address

101 6th Avenue, 3rd Floor
New York, NY
10013

Alerts

Be the first to know and let us send you an email when OS Therapies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to OS Therapies:

Shortcuts

Sponsored

Share

Nearby businesses